Avadel Pharmaceuticals announces publication of RESTORE data highlighting challenges with twice-nightly oxybates and strong patient preference for once-nightly LUMRYZ™ dosing (sodium oxybate) extended-release oral suspension (CIII)

Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of final data from the RESTORE open-label/switch study, demonstrating that people with narcolepsy prefer once-at-bedtime LUMRYZ versus a twice-nightly immediate-release oxybate treatment option.

What Caused a Patient’s Legs to Turn Blue?

The 24-hour news cycle is just as important to medicine as it is to politics, finance, or sports. At MedPage Today, new information is posted

August 20, 2023

Delayed puberty in boys could lead to new follow-up healthcare routines in the future

Swedish young men who went through late puberty during adolescence are more likely to use healthcare services later in life, according to research presented at

November 18, 2024

IG Live September 25: When the Healers Need Healing

In the high-stress environment of healthcare, where the focus is often on healing and saving the lives of patients, a quieter and significant struggle has

September 22, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.